SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas
SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas
复制标题
SATB2 是一种有前景的生物标志物，可用于识别肝转移性腺癌的结直肠起源
DOI：
10.1016/j.ebiom.2018.01.001
复制
发表时间：
2018-02-01
期刊：
影响因子：
11.1
通讯作者：
Cai, Mu-Yan
中科院分区：
文献类型：
--
作者：
Zhang, Yi-Jun;Chen, Jie-Wei;Cai, Mu-Yan
SATB2（富含特殊 AT 的序列结合蛋白 2）最近被证明是结直肠癌 (CRC) 的特异性生物标志物。本研究的目的是调查 SATB2 作为检测 CRC 肝转移来源的手段的诊断潜力。使用免疫组织化学 (IHC) 在 101 个 CRC 和 273 个非 CRC 腺癌样本的切除队列中检查 SATB2 表达。使用由 192 例肝活检组成的独立队列评估基于 SATB2 和 SATB2、CK20 和 CDX2 三标记物组的 CRC 肝转移起源的诊断准确性。 IHC 显示 101 个原发性 CRC 样本中的 97 个 (96.0%) 呈 SATB2 阳性，而 273 个其他癌症类型样本中只有 6 个 (2.1%) 呈 SATB2 阳性。切除样本中SATB2表达的敏感性、特异性和AUC值分别为97%、97.1%和0.977。同时，对于肝活检样本，CRC肝转移的敏感性、特异性和AUC值分别为：SATB2为92.2%、97.8%和0.948，CK20为95.1%、91.0%和0.959，CDX2为100%、85.4%和0.976。进一步分析表明，在活检取样的 92/103 (89.3%) CRC 和 2/89 (2.2%) 非 CRC 肝转移中检测到所有三标记物阳性。我们的研究结果表明，通过 IHC 测量的 SATB2 可以作为 CRC 转移的有前途的诊断生物标志物。将 SATB2 与 CK20 和 CDX2 的评估结合起来形成三标记物组，进一步改进了肝活检组织中转移性 CRC 的检测。 (c) 2018 年作者。由 Elsevier B.V 出版。这是一篇遵循 CC BY-NC-ND 许可的开放获取文章
SATB2 (Special AT-rich sequence-binding protein 2) has recently been shown to be a specific biomarker of colorectal cancer (CRC). The aim of this study was to investigate the diagnostic potential of SATB2 as a means of detecting a CRC origin for liver metastases. SATB2 expression was examined in a resection cohort of 101 CRC and 273 non-CRC adenocarcinoma samples using immunohistochemistry (IHC). The diagnostic accuracy of CRC origins of livermetastases based on SATB2 and a three marker panel of SATB2, CK20 and CDX2 was evaluated using an independent cohort of 192 liver biopsies. IHC showed 97 of the 101 (96.0%) primary CRC sampleswere SATB2 positive, compared to only 6 of the 273 (2.1%) samples of other cancer types. The sensitivity, specificity and AUC values of SATB2 expression in resection sampleswere 97%, 97.1% and 0.977, respectively. Meanwhile, for the liver biopsy samples, the sensitivity, specificity and AUC values of a CRC liver metastases was 92.2%, 97.8% and 0.948 for SATB2, 95.1%, 91.0% and 0.959 for CK20, and 100%, 85.4% and 0.976 for CDX2, respectively. Further analysis demonstrated that all three-marker positivity was detected in 92/103 (89.3%) CRC and 2/89 (2.2%) non-CRC livermetastases sampled by biopsy. Our findings suggest that SATB2, asmeasured by IHC, could serve as a promising diagnostic biomarker of CRC metastases. Combining evaluation of SATB2 with CK20 and CDX2 to form a three marker panel further improved the detection of metastatic CRCs in liver biopsy tissues. (c) 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license